SCHEMBL5332147

SCHEMBL5332147

Ic1ccc2occc2n1

nearest known ligand 0.46

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 4/20 0.46
CDK9 P50750 1/20 0.32
CYP2A6 P11509 2/20 0.31
CHRNA7 P36544 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5308681 0.73 DYRK1A (0.46) DYRK1ACDK9CYP2A6CHRNA7
SCHEMBL8312831 0.73 DYRK1A (0.46) DYRK1ACDK9CYP2A6
SCHEMBL17844802 0.73 DYRK1A (0.46) DYRK1ACDK9CYP2A6CHRNA7
SCHEMBL6647229 0.73 DYRK1A (0.59) DYRK1ACDK9
SCHEMBL31507530 0.73 DYRK1A (0.46) DYRK1ACDK9CYP2A6CHRNA7
SCHEMBL13666784 0.72 DYRK1A (0.42) DYRK1ACDK9
SCHEMBL16840467 0.70 NCF1 (0.45) DYRK1A
SCHEMBL18937628 0.69 DYRK1A (0.42) DYRK1ACDK9
SCHEMBL6432195 0.68 CYP2A6 (0.44) DYRK1ACDK9CYP2A6CHRNA7
SCHEMBL13668632 0.68 DYRK1A (0.46) DYRK1ACDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9902733-B2 Furopyridines as inhibitors of protein kinases MASARYKOVA UNIVERZITA (CH) 2018-02-27 US disclosed
US-9902733-B2 Furopyridines as inhibitors of protein kinases MASARYKOVA UNIVERZITA (CH) 2018-02-27 US disclosed
US-20170037052-A1 FUROPYRIDINES AS INHIBITORS OF PROTEIN KINASES MASARYKOVA UNIVERZITA (CZ) 2017-02-09 US disclosed
US-20170037052-A1 FUROPYRIDINES AS INHIBITORS OF PROTEIN KINASES MASARYKOVA UNIVERZITA (CZ) 2017-02-09 US disclosed
WO-2015165428-A1 FUROPYRIDINES AS INHIBITORS OF PROTEIN KINASES MASARYKOVA UNIVERZITA (CZ) 2015-11-05 WO disclosed
WO-2012124775-A1 NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND 田辺三菱製薬株式会社 (JP) 2012-09-20 WO disclosed
WO-2007039146-A1 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037052-A1 FUROPYRIDINES AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP4K2, MAP3K5 DYRK1A 402/4885CDK9 78/4885CYP2A6 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.